News Focus
News Focus
Post# of 257268
Next 10
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

Re: None

Wednesday, 05/25/2005 8:33:59 PM

Wednesday, May 25, 2005 8:33:59 PM

Post# of 257268
GTCB annual-meeting Q&A:

I just listened to the webcast Q&A and, unfortunately, only Dr. Cox (who was at the podium) is clearly audible. The questions themselves and the answers by the GTCB officers other than Dr. Cox are not audible.

I can fill in most of the blanks. These remarks are paraphrased and not necessarily verbatim accounts:

>>
Q1 (Dew): What does the EMEA inspection procedure consist of? Is there only one physical inspection of the sites at GTC and its manufacturing partner (Cambrex), or might there be a series of inspections? Does anyone at GTC have experience with these kinds of inspections?

A1: (Gregory Liposky, SVP of Operations): The Europeans generally like to wrap up everything in a single trip; GTCB personnel do indeed have experience with these procedures.

Q2 (Dew): The most recent SEC filing remarks on the shelf life of ATryn. Is this primarily an accounting matter, or is it a bone of contention with the Agency?

A2-1 (Richard Scotland, VP of Regulatory Affairs): [Sorry, I cannot remember the exact answer, but I know that it was reassuring.]
A2-2 (Dr. Cox): [Audible]

Q3 (Dew): In your presentation today, Suzanne (Suzanne Groet, VP of Therapeutic Protein Development) remarked that ATryn may have greater binding affinity to heparin than plasma-based antithrombin. Why is this important, and is this a feature of ATryn that will become part of the product label?

A3 (Dr. Cox): [Audible]

Q4 (Dew): A nomenclature question: is the "antithrombin alfa" name (the newly registered name for the active ingredient in ATryn) the successor to the "antithrombin-III" name?

A4-1 (Richard Scotland): AT-III refers to the plasma-based protein only, while antithrombin alfa refers to GTC’s recombinant protein.
A4-2 (Dr. Cox) [Audible]

Q5 (Dew): On your most recent conference call, I sensed a de-emphasis of GTC’s albumin program and an increased emphasis on the AAT program, Would you please comment on this?

A5 (Dr. Cox): [Audible]

Q6 (Urche): Would you update us on the malaria program?

A6 (Dr. Cox) [Audible]
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today